Agios Pharmaceuticals, Inc. (AGIO)
USD 39.02
(-7.01%)
USD 39.02
(-7.01%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 26.82 Million | 14.24 Million | - | 203.19 Million | 117.91 Million | 94.38 Million |
| Cost of Revenue | 9.5 Million | 1.7 Million | 18.77 Million | 2.8 Million | 1.31 Million | 1.39 Million |
| Gross Profit | 17.31 Million | 12.53 Million | -18.77 Million | 200.39 Million | 116.59 Million | 92.99 Million |
| Operating Expenses | 408.8 Million | 401.58 Million | 378.41 Million | 516.54 Million | 542.92 Million | 455.46 Million |
| Selling, General and Administrative Expenses | 119.9 Million | 121.67 Million | 121.44 Million | 149.07 Million | 132.03 Million | 114.14 Million |
| Research and Development Expenses | 288.9 Million | 279.91 Million | 256.97 Million | 367.47 Million | 410.89 Million | 341.32 Million |
| Other Expenses | - | 6.74 Million | 14.43 Million | - | - | - |
| Cost and Expenses | 418.31 Million | 403.28 Million | 378.41 Million | 519.34 Million | 544.24 Million | 456.86 Million |
| Operating Income | -391.48 Million | -389.04 Million | -378.41 Million | -316.14 Million | -426.33 Million | -362.47 Million |
| Interest Expense | - | 12.79 Million | - | 17.83 Million | - | 16.45 Million |
| Income Tax Expense | - | -157.24 Million | -1.97 Billion | 7.84 Million | -14.86 Million | 32.9 Million |
| Earnings before Tax | -352.08 Million | -231.8 Million | -356.51 Million | -327.37 Million | -411.47 Million | -346.02 Million |
| Net Income | -352.08 Million | -74.55 Million | 1.6 Billion | -335.21 Million | -396.61 Million | -346.02 Million |
| Earnings Per Share Basic | -6.33 | -1.36 | 26.55 | -4.86 | -6.61 | -6.03 |
| Earnings Per Share Diluted | -6.33 | -1.36 | 26.55 | -4.86 | -6.61 | -6.03 |
| Weighted Average Shares Outstanding | 55.65 Million | 54.78 Million | 60.44 Million | 68.99 Million | 59.99 Million | 57.41 Million |
| Weighted Average Shares Outstanding (Diluted) | 55.65 Million | 54.78 Million | 60.44 Million | 68.99 Million | 59.99 Million | 57.41 Million |
| Gross Margin | 0.65 | 0.88 | - | 0.99 | 0.99 | 0.99 |
| EBIT Margin | -14.35 | -36.99 | - | -1.52 | -3.55 | -3.84 |
| Profit Margin | -13.13 | -5.24 | - | -1.65 | -3.36 | -3.67 |
| EBITDA | -384.86 Million | -380.48 Million | -337.73 Million | -326.12 Million | -394.85 Million | -338.85 Million |
| Earnings Before Tax Margin | -14.60 | -27.32 | - | -1.56 | -3.62 | -3.84 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 8.96 Million | 8.61 Million | 8.18 Million | 26.82 Million | 7.1 Million | 7.39 Million |
| Cost of Revenue | 783 Thousand | 3.08 Million | 1.97 Million | 9.5 Million | 1.98 Million | 633 Thousand |
| Gross Profit | 8.18 Million | 5.52 Million | 6.21 Million | 17.31 Million | 5.11 Million | 6.76 Million |
| Operating Expenses | 110.99 Million | 111.34 Million | 98.28 Million | 408.8 Million | 111.39 Million | 107.66 Million |
| Selling, General and Administrative Expenses | 38.53 Million | 35.53 Million | 31.01 Million | - | 35.3 Million | 25.82 Million |
| Research and Development Expenses | 72.45 Million | 75.8 Million | 67.27 Million | - | 76.08 Million | 81.84 Million |
| Other Expenses | 1.34 Million | 1.57 Million | 1.63 Million | 6.05 Million | 1.71 Million | 1.19 Million |
| Cost and Expenses | 111.77 Million | 114.43 Million | 100.26 Million | 418.31 Million | 113.38 Million | 108.29 Million |
| Operating Income | -102.81 Million | -105.81 Million | -92.07 Million | -391.48 Million | -106.27 Million | -100.89 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 53.12 Million | - | 1.3 Million | 6.45 Million | 1.35 Million | -9.99 Million |
| Earnings before Tax | 1 Billion | -96.11 Million | -81.54 Million | -352.08 Million | -95.94 Million | -91.32 Million |
| Net Income | 947.91 Million | -96.11 Million | -81.54 Million | -352.08 Million | -95.94 Million | -91.32 Million |
| Earnings Per Share Basic | 16.65 | -1.69 | -1.45 | - | -1.72 | -1.64 |
| Earnings Per Share Diluted | 16.22 | -1.69 | -1.45 | - | -1.72 | -1.64 |
| Weighted Average Shares Outstanding | 56.93 Million | 56.8 Million | 56.38 Million | 55.65 Million | 55.89 Million | 55.8 Million |
| Weighted Average Shares Outstanding (Diluted) | 58.43 Million | 56.8 Million | 56.38 Million | 55.65 Million | 55.89 Million | 55.8 Million |
| Gross Margin | 0.91 | 0.64 | 0.76 | 0.65 | 0.72 | 0.91 |
| EBIT Margin | -11.47 | -12.10 | -11.08 | - | -14.76 | -13.64 |
| Profit Margin | 105.75 | -11.16 | -9.96 | -13.13 | -13.51 | -12.34 |
| EBITDA | -102.81 Million | -104.22 Million | -90.72 Million | - | -104.87 Million | -100.89 Million |
| Earnings Before Tax Margin | -11.47 | -12.28 | -11.24 | -14.60 | -14.96 | -13.64 |
CLNN
LSTR
THC
THCBF
FHLD
UTLH